B cell targeted therapy for immunoglobulin G4-related disease.

IF 2.7 Q3 IMMUNOLOGY
Immunological Medicine Pub Date : 2021-12-01 Epub Date: 2021-02-14 DOI:10.1080/25785826.2021.1886630
Motohisa Yamamoto
{"title":"B cell targeted therapy for immunoglobulin G4-related disease.","authors":"Motohisa Yamamoto","doi":"10.1080/25785826.2021.1886630","DOIUrl":null,"url":null,"abstract":"<p><p>Glucocorticoids are the first-line drug for the remission induction therapy of immunoglobulin (Ig) G4-related disease. Achieving drug-free remission using glucocorticoids alone is difficult, however, and many patients require maintenance therapy with glucocorticoids and immunosuppressants. Studies have recently found that the number of peripheral memory B cells and plasmablasts is increased in IgG4-related disease and have indicated the efficacy of rituximab, which, in remission induction therapy, rapidly reduces serum IgG4 levels and has the tapering effect of glucocorticoids. Rituximab has been shown to reduce the risk of relapse more than oral immunosuppressants such as azathioprine. However, maintaining drug-free remission is difficult with a single course of rituximab alone, and many cases require maintenance therapy with rituximab. This article outlines the potential of B-cell targeted therapy, focusing on the efficacy, and safety of rituximab for IgG4-related disease.</p>","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":"44 4","pages":"216-222"},"PeriodicalIF":2.7000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/25785826.2021.1886630","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunological Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/25785826.2021.1886630","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/2/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 10

Abstract

Glucocorticoids are the first-line drug for the remission induction therapy of immunoglobulin (Ig) G4-related disease. Achieving drug-free remission using glucocorticoids alone is difficult, however, and many patients require maintenance therapy with glucocorticoids and immunosuppressants. Studies have recently found that the number of peripheral memory B cells and plasmablasts is increased in IgG4-related disease and have indicated the efficacy of rituximab, which, in remission induction therapy, rapidly reduces serum IgG4 levels and has the tapering effect of glucocorticoids. Rituximab has been shown to reduce the risk of relapse more than oral immunosuppressants such as azathioprine. However, maintaining drug-free remission is difficult with a single course of rituximab alone, and many cases require maintenance therapy with rituximab. This article outlines the potential of B-cell targeted therapy, focusing on the efficacy, and safety of rituximab for IgG4-related disease.

免疫球蛋白g4相关疾病的B细胞靶向治疗。
糖皮质激素是免疫球蛋白(Ig) g4相关疾病缓解诱导治疗的一线药物。然而,仅使用糖皮质激素实现无药物缓解是困难的,许多患者需要糖皮质激素和免疫抑制剂的维持治疗。最近的研究发现,在IgG4相关疾病中,外周记忆B细胞和质母细胞的数量增加,并表明了利妥昔单抗的疗效,在缓解诱导治疗中,利妥昔单抗可迅速降低血清IgG4水平,并具有糖皮质激素的逐渐减少作用。利妥昔单抗已被证明比口服免疫抑制剂如硫唑嘌呤更能降低复发风险。然而,单疗程的利妥昔单抗很难维持无药缓解,许多病例需要利妥昔单抗维持治疗。本文概述了b细胞靶向治疗的潜力,重点是利妥昔单抗治疗igg4相关疾病的疗效和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Immunological Medicine
Immunological Medicine Medicine-Immunology and Allergy
CiteScore
7.10
自引率
2.30%
发文量
19
审稿时长
19 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信